摘要
目的研究C-erbB-2、雌激素受体(ER)和孕激素受体(PR)在乳腺癌中的表达及其与患者年龄、肿瘤大小、淋巴结转移、组织病理学类型及肿瘤分期的关系和临床意义。方法应用免疫组化法检测83例乳腺癌中C-erbB-2、ER和PR的表达,分析其与临床病理特征的关系。结果83例乳腺癌中C-erbB-2、ER和PR的表达阳性率分别为78.3%、56.6%和55.4%。C-erbB-2、ER和PR的表达在患者不同的年龄、肿瘤大小、组织病理学类型及肿瘤分期之间的差异均无统计学意义(P>0.05);ER和PR的表达在有无淋巴结转移之间差异无统计学意义(P>0.05);C-erbB-2的表达在有无淋巴结转移之间的差异有统计学意义(P<0.05),且它们之间呈正相关(r=0.387,P<0.05)。结论C-erbB-2是判断乳腺癌淋巴结转移的重要指标之一,联合检测ER和PR更有助于乳腺癌患者的临床治疗和预后判断。
Objective To investigate the expressions of C-erbB-2, estrogen receptor （ER） and progesterone receptor （PR） in breast cancer tissues and to explore their relationship with patients＇ age, tumor size, lymph node metastasis, histopathological type and the stage of cancer. Methods The expressions of C-erbB-2, ER and PR in 83 cases of breast cancer tissues were detected by immunohistochemistry and the clinical significance was statistically analyzed, Results The positive expression rate of C-erbB-2, ER and PR in 83 cases of breast cancer tissues were 78.3%, 56.6% and 55.4%, respectively. The expressions of C-erbB-2, ER and PR were not correlated to patients＇ age, tumor size, histopathological type and the stage of cancer （P〉0.05）. While the expression of C-erbB-2 rather than ER and PR was correlated to lymph node metastasis （P〈 0. 05） and the correlation was positive （r= 0. 387, P〈0.05）. Conclusion The positive expression of C-erbB-2 is one of lymph node metastasis factors for breast cancer patients. Combined detection of ER and PR expression may be helpful to clinical treatment and predict prognosis for breast cancer patients.
出处
《中国普外基础与临床杂志》
CAS
2009年第7期518-521,共4页
Chinese Journal of Bases and Clinics In General Surgery
